BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...

Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved ...

BioNTech (BNTX) shares have been on a bit of a ride recently, with the latest movement sparking conversations among those watching the biotech space. Investors are weighing the stock’s performance ...

In earlier laboratory experiments, researchers had observed that mRNA vaccines improve the effectiveness of cancer drugs such ...

An announcement from BioNTech SE ( (BNTX) ) is now available.

Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...

BioNTech (BNTX) announced it had commenced its public exchange offer for all outstanding shares of CureVac (CVAC). The Offer is being made ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize ...

CureVac shareholders receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar; an indicative exchange ratio will be available at ...

BofA analyst Tazeen Ahmad lowered the firm’s price target on BioNTech (BNTX) to $130 from $134 and keeps a Buy rating on the shares. The firm ...

BioNTech , first in the race to disclose interim data from a large-scale trial showing a highly effective COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and ...